HEALTHMEDPAGE TODAY
Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss?
Updated phase II data from the VESPER program showed that patients achieved weight loss with weekly doses of the investigational GLP-1 agonist berobenatide. The study, presented at the American Diabetes Association annual meeting, is exploring whether monthly dosing can maintain these results.
Mentioned
Related Signal
Adjacent reporting
- STAT+: Detailed data show Pfizer’s monthly obesity drug continues to show potential
- Monthly GLP-1 for Obesity Promising as More Manageable Alternative
- Pfizer's monthly weight loss shot posted side effects similar to Wegovy in mid-stage trial
- Experimental obesity drug outperforms traditional weight-loss treatments in early research
- The next goal for weight loss drugs? Fewer injections